MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant As First-Line and Second-Line Therapy for HR+, HER2--Advanced Breast Cancer
CLINICAL CANCER RESEARCH(2021)
Key words
Metastatic Breast Cancer
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined